e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Treatment of tuberculosis at times of emerging drug resistance
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MDR/XDR-TB treatment outcome
A. Skrahina, H. Hurevich, A. Astrauko, A. Skrahin, L. Surkova (Minsk, Belarus)
Source:
Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Session:
Treatment of tuberculosis at times of emerging drug resistance
Session type:
E-Communication Session
Number:
210
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Skrahina, H. Hurevich, A. Astrauko, A. Skrahin, L. Surkova (Minsk, Belarus). MDR/XDR-TB treatment outcome. Eur Respir J 2009; 34: Suppl. 53, 210
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Clinical management improves the treatment outcome of MDR-TB patients
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB
Source: Breathe 2008; 6: 161
Year: 2009
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
The effect of resection surgery on long-term treatment outcomes of patients with MDR/XDR-TB
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017
Long-term effectiveness of surgery treatment of TB patients
Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations
Year: 2020
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017
Year: 2017
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
Standardized second-line anti-TB treatment of multidrug-resistant tuberculosis during pregnancy; maternal and neonatal safety and outcome
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Year: 2010
Treatment outcomes for XDR TB patients with surgery
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Poor treatment outcomes of XDR-TB patients in resource-limited settings
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017
Year: 2017
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010
Does gender has any effect on tuberculosis diagnosis and treatment outcomes?
Source: Eur Respir J 2003; 22: Suppl. 45, 520s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept